Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Dimerix Limited ( (AU:DXB) ) is now available.
Dimerix Limited announced a change in the director’s interest, specifically regarding the acquisition of unlisted options by Director Nina Webster. This change is part of the company’s Omnibus Equity Plan, reflecting strategic moves to align management interests with shareholder value. The issuance of these options, valued at $1,093,500, indicates confidence in the company’s future growth and operational strategies.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on developing innovative pharmaceutical products. The company is involved in creating therapies for unmet medical needs, particularly in the area of kidney disease and other inflammatory conditions.
Average Trading Volume: 1,175,581
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$345.2M
See more data about DXB stock on TipRanks’ Stock Analysis page.